63237-87-6

Usage

Uses

Used in Pharmaceutical Industry:
PYRAZOLO[1,5-A]PYRIDINE-2,3-DICARBOXYLIC ACID is used as a potential anti-inflammatory and analgesic agent for its potential to alleviate inflammation and pain.
Used in Neurodegenerative Disease Treatment:
PYRAZOLO[1,5-A]PYRIDINE-2,3-DICARBOXYLIC ACID is used as a potential therapeutic agent for the treatment of neurodegenerative diseases, due to its investigational properties in managing such conditions.
Used in Organic Synthesis and Medicinal Chemistry:
PYRAZOLO[1,5-A]PYRIDINE-2,3-DICARBOXYLIC ACID is used as a key intermediate in the development of new drugs and pharmaceuticals, contributing to the advancement of organic synthesis and medicinal chemistry.

InChI:InChI=1/C9H6N2O4/c12-8(13)6-5-3-1-2-4-11(5)10-7(6)9(14)15/h1-4H,(H,12,13)(H,14,15)

Upstream product

• 5825-71-8 pyrazolo<1,5-a>pyridine-2,3-dicarboxylic acid dimethyl ester 
• 25275-41-6 N-iminopyridinium ylide 
• 110-86-1 pyridine 

Downstream Products

• 80537-11-7 Pyrazolo[1,5-a]pyridine-2,3-dicarboxylic acid bis-phenylamide 
• 63237-88-7 pyrazolo[1,5-a]pyridine-2-carboxylic acid 
• 80537-14-0 ethyl pyrazolo<1,5-a>pyridine-2-carboxylate 
• 80537-15-1 pyrazolo<1,5-a>pyridine-2-carboxhydrazide 
• 885275-10-5 pyrazolo[1,5-a]pyridine-2-carbaldehyde 

Relevant academic research and scientific papers

Regioselective Synthesis of New 2,4-(Het)aryl-3H-pyrido[1′,2′:1,5]pyrazolo[4,3-d]pyrimidines Involving Palladium-Catalyzed Cross-Coupling Reactions

The design of some novel di-(het)arylated-3H-pyrido[1′,2′:1,5]pyrazolo[4,3-d]pyrimidine derivatives is reported. The series was developed from 1-aminopyridinium iodide, which afforded the key intermediate bearing two thiomethyl and amide functions, each of them useful for palladium catalyzed cross coupling reactions by alkyl sulfur release and C-O activation, respectively. The two regioselective and successive cross-coupling reactions were first carried out in C-4 by in situ C-O activation and next in C-2 by a methylsulfur release. Process optimization furnished conditions leading to products in high yields. The scope and limitations of the methodologies were evaluated and the final compounds characterized.

SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel spiro-oxadiazoline compounds that are suitable as agonists or partial agonists of a7-nAChR, and pharmaceutical compositions of the same, methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering a spiro-oxadiazoline cx7-nAChR agonist or partial agonist, to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

1,3-Dipolar Addition of Pyridine N-Imine to Acetylenes and the Use of C-13 NMR in Several Structural Assignments

Addition of pyridine-N-imine to a variety of acetylenic mono- (Scheme I) and di- (Scheme II) carboxylic ester dipolarophiles was carried out.Several of the 3-azapyrrocoline esters obtained were further converted into acids, amides and hydrazides as shown in Schemes I and II.